March 29, 2024

Omics-based Clinical Trials Market Size to Hit US$ 50.5 billion by 2030

The global omics-based clinical trials market size was valued at USD 25.2 billion in 2020, and is predicted to be worth around USD 50.5 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.

Omics-based Clinical Trials Market (By Product: Phase I, Phase II, Phase III, Phase IV; By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies; By Indication : Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases (includes the rare diseases), Others (includes ophthalmic, ear diseases, etc)) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030

Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/39105

Report Coverage

Report ScopeDetails
Market SizeUS$ 50.5 billion by 2030
Growth RateCAGR of 6.4% From 2022 to 2030
Largest MarketNorth America
Base Year2021
Forecast Period2022 to 2030
Segments CoveredPhase, Study design, Indication

Growth Factors

Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix – omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The demand is growing for a pattern shift toward the stratification of patients or even personalized medicine. There are several complex diseases that urgently need a better understanding of their analysis and more effective therapeutic strategies. Currently, omics-based studies make the majority of precision medicine-based data, e.g. DNA sequencing technique is already being used to identify genetic material that enhances specific cancers.

Key Players

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

Market Segmentation

  • By Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • By Study Design
    • Interventional Studies
    • Observational Studies
    • Expanded Access Studies
  • By Indication
    • Oncology
    • Cardiology
    • Respiratory Diseases
    • Skin Diseases
    • CNS Diseases
    • Immunology
    • Genetic Diseases (includes the rare diseases)
    • Others (includes ophthalmic, ear diseases, etc)
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
  • Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39105

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2019-2021) and forecast (2022-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Omics-Based Clinical Trials Market, By Phase

7.1.  Omics-Based Clinical Trials Market, by Phase, 2021-2030

7.1.1.    Phase I

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Phase II

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Phase III

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Phase IV

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Omics-Based Clinical Trials Market, By Study Design

8.1.  Omics-Based Clinical Trials Market, by Study Design, 2021-2030

8.1.1.    Interventional Studies

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Observational Studies

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Expanded Access Studies

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Omics-Based Clinical Trials Market, By Indication

9.1.  Omics-Based Clinical Trials Market, by Indication, 2021-2030

9.1.1.    Oncology

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cardiology

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Respiratory Diseases

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Skin Diseases

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    CNS Diseases

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Immunology

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Genetic Diseases (includes the rare diseases)

9.1.7.1.        Market Revenue and Forecast (2017-2030)

9.1.8.    Others (includes ophthalmic, ear diseases, etc)

9.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Omics-Based Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.1.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.1.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.2.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.2.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.3.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.3.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.4.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.4.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.5.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.5.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

Chapter 11.  Company Profiles

11.1.              Parexel International Corporation

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Pharmaceutical Product Development (PPD)

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Charles River Laboratory

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              ICON plc

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              SGS SA

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Eli Lilly and Company

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Pfizer Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Covance Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Novo Nordisk

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Rebus Bio

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39105

About Us: Our team of skilled and experienced analysts specializes in troubleshooting problems faced by our clients. For comprehensive summary of our services and market research requirements for Global industry.

Contact Us:

call: +1 9197 992 333

Vision Research Report

Any Assistance, Email – sales@visionresearchreports.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →